Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously...
11 insider purchases on record · latest filing 2026-05-13.
Insiders have also filed 32 sale transactions at VRDN.